In vivo tumor-transplant models showed that the DPP4 inhibitor sitagliptin reduced tumor growth through the preservation of bioactive CXCL10 in the TME of melanoma and colon carcinoma. The gene discussed is CXCL10; the disease is colon carcinoma.